» Articles » PMID: 29140298

Enhancement of Bone Marrow-Derived Mesenchymal Stem Cell Osteogenesis and New Bone Formation in Rats by Obtusilactone A

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2017 Nov 16
PMID 29140298
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The natural pure compound obtusilactone A (OA) was identified in Kanehira & Sasaki, and shows effective anti-cancer activity. We studied the effect of OA on osteogenesis of bone marrow-derived mesenchymal stem cells (BMSCs). OA possesses biocompatibility, stimulates Alkaline Phosphatase (ALP) activity and facilitates mineralization of BMSCs. Expression of osteogenesis markers , , , and was enhanced in OA-treated BMSCs. An in vivo rat model with local administration of OA via needle implantation to bone marrow-residing BMSCs revealed that OA increased the new bone formation and trabecular bone volume in tibias. Micro-CT images and H&E staining showed more trabecular bone at the needle-implanted site in the OA group than the normal saline group. Thus, OA confers an osteoinductive effect on BMSCs via induction of osteogenic marker gene expression, such as BMP2 and Runx2 expression and subsequently elevates ALP activity and mineralization, followed by enhanced trabecular bone formation in rat tibias. Therefore, OA is a potential osteoinductive drug to stimulate new bone formation by BMSCs.

Citing Articles

Fabrication of Grown Hydroxyapatite Nanoparticles Modified Porous Polyetheretherketone Matrix Composites to Promote Osteointegration and Enhance Bone Repair.

Wang N, Qi D, Liu L, Zhu Y, Liu H, Zhu S Front Bioeng Biotechnol. 2022; 10:831288.

PMID: 35295654 PMC: 8919038. DOI: 10.3389/fbioe.2022.831288.


Interaction of obtusilactone B and related butanolide lactones with the barrier-to-autointegration factor 1 (BAF1). A computational study.

Bailly C, Vergoten G Curr Res Pharmacol Drug Discov. 2021; 2:100059.

PMID: 34909681 PMC: 8663951. DOI: 10.1016/j.crphar.2021.100059.


Osteogenic ability using porous hydroxyapatite scaffold-based delivery of human placenta-derived mesenchymal stem cells.

Ren X, Wang Q, Liu C, Zhao Q, Zheng J, Tian K Exp Ther Med. 2021; 22(4):1091.

PMID: 34504545 PMC: 8383769. DOI: 10.3892/etm.2021.10525.


An Intermediate Concentration of Calcium with Antioxidant Supplement in Culture Medium Enhances Proliferation and Decreases the Aging of Bone Marrow Mesenchymal Stem Cells.

Yang C, Chuang S, Cheng T, Lee M, Chen H, Lin S Int J Mol Sci. 2021; 22(4).

PMID: 33672524 PMC: 7923799. DOI: 10.3390/ijms22042095.

References
1.
Chen G, Deng C, Li Y . TGF-β and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci. 2012; 8(2):272-88. PMC: 3269610. DOI: 10.7150/ijbs.2929. View

2.
Chen C, Lo W, Liu Y, Chen C . Chemical and cytotoxic constituents from the leaves of Cinnamomum kotoense. J Nat Prod. 2006; 69(6):927-33. DOI: 10.1021/np060107l. View

3.
Cancedda R, Bianchi G, Derubeis A, Quarto R . Cell therapy for bone disease: a review of current status. Stem Cells. 2003; 21(5):610-9. DOI: 10.1634/stemcells.21-5-610. View

4.
Rosset P, Deschaseaux F, Layrolle P . Cell therapy for bone repair. Orthop Traumatol Surg Res. 2014; 100(1 Suppl):S107-12. DOI: 10.1016/j.otsr.2013.11.010. View

5.
Chang C, Wang C, Chang J, Hsu C, Ho M . The susceptive alendronate-treatment timing and dosage for osteogenesis enhancement in human bone marrow-derived stem cells. PLoS One. 2014; 9(8):e105705. PMC: 4144913. DOI: 10.1371/journal.pone.0105705. View